See the DrugPatentWatch profile for Aimovig
What is Aimovig?
Aimovig (erenumab) is a biologic medicine used to prevent migraine in adults. It is a human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) pathway, helping reduce the frequency of migraine attacks.
Is Aimovig actually a biologic?
Yes. Aimovig is classified as a biologic because it is a monoclonal antibody produced through biological processes, not a traditional small-molecule drug.
How does Aimovig work for migraine prevention?
Aimovig binds to CGRP (a signaling molecule involved in migraine biology). By blocking CGRP’s activity, it helps prevent migraines before they start rather than treating acute attacks after they begin.
What do patients usually need to know about dosing?
Aimovig is given as an injection (self-administered). The typical preventive dosing schedule is monthly, but the exact dose used can depend on the patient’s prescribed regimen.
How long does Aimovig take to work?
Responses vary by person. Many patients and clinicians judge effectiveness based on whether migraine days decrease over subsequent months of treatment rather than after only one dose.
What’s the main difference between Aimovig and other migraine preventives?
Aimovig targets CGRP directly using an antibody. Other preventive options may include different drug classes (for example, oral preventives or other biologics that target CGRP or its receptor). Those class differences can affect which patients respond best and what side effects are most relevant.
Where can I check patents and market exclusivity for Aimovig?
If you are looking for patent or exclusivity detail on Aimovig (erenumab), DrugPatentWatch.com tracks publicly available patent information and related documents. You can search Aimovig directly here: https://www.drugpatentwatch.com/